I-AASraw ivelisa i-NMN kunye ne-NRC powders ngobuninzi!

Erlotinib

Akukho kalo Udidi:

U-Erlotinib Powder, othengiswa phantsi kwegama lophawu lwe-Tarceva phakathi kwabanye, liyeza elisetyenziselwa ukunyanga umhlaza wamaphaphu ongekho mncinci (NSCLC) kunye nomhlaza wepancreatic. Ngokukodwa isetyenziselwa i-NSCLC kunye notshintsho kwi-epidermal factor factor receptor (EGFR) -kuba kukususwa kwe-exon 19 ukususwa (del19) okanye i-exon 21 (L858R) yokutshintsha-ethe yasasazeka kwamanye amalungu omzimba.

Ingcaciso yeMveliso

Iimpawu ezisisiseko

Igama lemveliso I-Erlotinib powder
Inani leCAS 183321-74-6
I-Molecular Formula C22H23N3O4
Ubukhulu beFormula 393.443
Iintetho ezifanayo CP-358774;

OSI774;

Erlotinib powder isiseko sasimahla;

183321-74-6.

Kubonakala I-White ukuya kumhlophe i-crystalline powder
Ukugcina nokuPhatha Okomileyo, omnyama kunye no-0 ukuya ku-4 C okwexesha elifutshane (iintsuku ukuya kwiiveki) okanye -20 C ixesha elide (iinyanga ukuya kwiminyaka).

 

Inkcazo yePowder ye-Erlotinib

I-Erlotinib powder, ithengiswa phantsi kwegama legama elithi Tarceva phakathi kwabanye, iyeza elisetyenziselwa ukunyanga umhlaza wamaphaphu ongaqhelekanga (NSCLC) kunye nomhlaza wepancreatic. Ngokukodwa isetyenziselwa i-NSCLC kunye notshintsho kwi-epidermal factor factor receptor (EGFR) -kuba kukususwa kwe-exon 19 ukususwa (del19) okanye i-exon 21 (L858R) yokutshintsha-ethe yasasazeka kwamanye amalungu omzimba. Kuthathwa ngomlomo.

I-Erlotinib powder sisiphumo sequinazoline esineepropathi ze-antineoplastic. Ukuncintisana ne-adenosine triphosphate, i-erlotinib powder iphinda ibophele kwi-intracellular catalytic domain ye-epidermal factor factor receptor (EGFR) tyrosine kinase, ngaloo ndlela ibuyisela ukuthintela i-phosphorylation ye-EGFR kunye nokuthintela ukuhanjiswa kwemiqondiso kunye neziphumo ze-tumorigenic ezinxulumene nokusebenza kwe-EGFR.

I-Erlotinib powder yavunywa ukuba isetyenziswe kwezonyango e-United States ngo-2004. IkuLuhlu lwaMayeza aBalulekileyo kuMbutho wezeMpilo weHlabathi, noludwelisa amayeza akhuselekileyo nafanelekileyo asebenza kwinkqubo yezempilo.

 

Indlela yokusebenza ye-Erlotinib Powder

I-Erlotinib powder yinto yokukhula kwe-epidermal factor receptor inhibitor (i-EGFR inhibitor). Iyeza lilandela i-Iressa (gefitinib), eyayilichiza lokuqala lolu hlobo.

I-Erlotinib powder ijolise ngokukodwa kwi-epidermal factor factor receptor (EGFR) tyrosine kinase, ebonakaliswa kakhulu kwaye ngamanye amaxesha iguqulwa ngeendlela ezahlukeneyo zomhlaza. Ibopha ngendlela eguqukayo kwi-adenosine triphosphate (ATP) yokubopha indawo yokwamkela. Ukuze umqondiso uhanjiswe, iimolekyuli ezimbini ze-EGFR kufuneka zidibane zenze i-homodimer.

Ezi ke zisebenzisa imolekyuli ye-ATP ukuhambisa i-phosphorylate enye kwenye intsalela ye-tyrosine, evelisa intsalela ye-phosphotyrosine, ekufuneni iiproteni ezibopha i-phosphotyrosine kwi-EGFR ukudibanisa iiprotein ezihambisa umqondiso we-cascades kwi-nucleus okanye isebenze ezinye iinkqubo ze-biochemical cellular. Xa i-erlotinib powder ibopha kwi-EGFR, ukuyilwa kweentsalela ze-phosphotyrosine kwi-EGFR akunakwenzeka kwaye imiqondiso yecascad ayiqalwanga.

I-Erlotinib powder nayo i-tyrosine kinase receptor inhibitor esetyenziswa kunyango lwe-pancreatic eqhubekekayo okanye ye-metastatic okanye umhlaza wamaphaphu ongaqhelekanga. Unyango lwe-Erlotinib powder ludityaniswa nokuphakama okwethutyana kumanqanaba e-serum aminotransferase ngexesha lonyango kunye neemeko ezinqabileyo zokonzakala kwesibindi.

 

Isicelo sePerlotinib Powder 

I-Erlotinib powder yinto enokubuyiselwa kwisizukulwana sokuqala i-receptor tyrosine kinase inhibitor (kunye neGefitinib) esebenza ikakhulu kwi-epidermal grow factor receptor (EGFR), ilungu losapho lwe-ErbB receptor. Iyeza linxibelelana nazo zombini iintlobo zasendle kunye notshintsho lwe-EGFR. Usapho lwe-ErbB lungenza ii-homodimers okanye ii-heterodimers, ezihlala zibangelwa ziziphumo ezisezantsi kunye ne-pathogenesis yeentlobo ezininzi ze-carcinomas ezifundwe ebantwini. I-Receptor tyrosine kinase inhibitors (TKI) ithintela iphosphorylation ye-substrate yayo kwindlela yokubonisa iseli. I-EGFR ihlala idlala indima kwimisebenzi emininzi yeselula, kubandakanya ukwahlulahlula, ukwanda, kunye ne-angiogenesis, zonke ezo ziimpawu zomhlaza.

Utshintsho lwe-EGFR kwi-NSCLC sisenzo esisebenzayo. Ezinye zeempawu zesigulana ezenza ukuba ubukho bokutshintsha kwe-EGFR kusenokwenzeka ukuba kungabikho nembali yokutshaya eqinisekisile i-adenocarcinoma ngohlalutyo lwembali, ubuhlanga baseAsia, kunye nesini sabasetyhini. Utshintsho lwesibini kwi-EGFR luqhele ukwenzeka, oluchazwa leli nqaku ngezantsi.

 

Iziphumo ebezingalindelekanga ze-Erlotinib Powder kunye nesilumkiso

Iziphumo zilandelayo ziqhelekileyo kwizigulana ezithatha i-Erlotinib Powder:

▪ Irhashalala

▪ Urhudo

▪ Ukungatyi kakuhle

▪ Ukudinwa

▪ Umphefumlo omfutshane

▪ Khohlela

▪ Isicaphucaphu nokugabha

 

Iziphumo ebezingalindelekanga ziziphumo ebezingalindelekanga eziqhelekileyo kwizigulana ezifumana i-Erlotinib Powder:

▪ Usulelo

Izilonda zomlomo

▪ Ukurhawuzelela

▪ Isikhumba esomileyo

▪ Ukucaphuka kwamehlo

▪ Intlungu esiswini

 

Ayizizo zonke iziphumo ebezingalindelekanga ezidweliswe apha ngasentla. Ezinye ezinqabileyo (ezenzeka ngaphantsi kwe-10% yezigulana) azidweliswanga apha. Nangona kunjalo, kuya kufuneka usoloko umazisa umboneleli wakho wezempilo ukuba ufumana naziphi na iimpawu ezingaqhelekanga.

 

isingqiniso

[1] UGao JW, Zhan P, Qiu XY, uJin JJ, uLv TF, Ingoma Y. Erlotinib esekwe kunyango olujolise kunyango ngokuchasene ne-erlotinib powder yodwa kunyango lwangaphambili olungasasebenziyo lomhlaza wamaphaphu: uhlalutyo lwe-meta-24 izilingo ezilawulwayo. Ukhenketho. Ngo-2017 ngoMeyi 31; 8 (42): 73258-73270. ikhonkco: 10.18632 / oncotarget.18319. UCollection 2017 Sep 22. Uphengululo. Ipapashwe kwi-PMID: 29069867; Ipapashwe kwi-PMCID eseMbindini: PMC5641210.

[2] Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T , Yang JC. I-Gefitinib okanye i-Erlotinib powder vs Chemotherapy ye-EGFR ye-Mutation-Positive Lung Cancer: Idatha nganye yesigulana iMeta-Uhlalutyo lokusinda ngokubanzi. J Natl Umhlaza Inst. Ngo-2017 uJun 1; 109 (6). ikhonkco: 10.1093 / jnci / djw279. Uphononongo. I-PMID epapashiweyo: 28376144.

[3] Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Ukuthelekiswa kwe-gefitinib, i-erlotinib powder kunye ne-afatinib kumhlaza wesifo somhlaza ongaqhelekanga: Uhlalutyo lwe-meta. Int J Umhlaza. Ngo-2017 uJuni 15; 140 (12): 2805-2819. ikhonkco: 10.1002 / ijc.30691. Epub 2017 Mar 27. Ukuphononongwa. Ipapashwe kwi-PMID: 28295308.

[4] "I-Erlotinib powder (Tarceva) Sebenzisa ngexesha lokukhulelwa". Iziyobisi.com. Ngomhla woku-1 kuNovemba ngo-2019. Ibuyisiwe nge-23 kaDisemba ngo-2019.

[5] "Erlotinib powder Monograph yeeNgcali". Iziyobisi.com. Ukufunyanwa kwe-12 kaNovemba ngo-2019.

[6] “Itarceva-erlotinib powder ityhidrokloride ipilisi”. Yonke imihla. 12 Disemba 2018. Ibuyiswe nge-23 ngoDisemba 2019.

[7] "Ipakethe yokuvunywa kweziyobisi: Tarceva (Erlotinib powder) NDA # 021743". Ulawulo lwezoKutya kunye noLawulo lweziyobisi (FDA). Ngomhla wama-28 ku-Matshi 2005. Ibuyisiwe nge-23 kaDisemba ngo-2019.

[8] URaymond E, uFaivre S, uArmand JP (2000). "Ukukhula kwe-Epidermal factor receptor tyrosine kinase njengeyona nto kujoliswe kuyo kunyango lwe-anticancer". Iziyobisi. 60 Suppl 1: 15-23, ingxoxo 41–2. ikhonkco: 10.2165 / 00003495-200060001-00002. IINKCUKACHA: I-PMID 11129168. S2CID 10555942.